MARKSANS PHARMA
|
MARKSANS PHARMA Last 5 Year Financial Ratios History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 8.40 | 6.92 | 5.88 | 4.51 | 5.76 |
| CEPS(Rs) | 10.28 | 8.59 | 7.00 | 5.66 | 6.71 |
| DPS(Rs) | 0.80 | 0.60 | 0.50 | 0.25 | 0.25 |
| Book NAV/Share(Rs) | 54.44 | 45.57 | 38.51 | 27.10 | 21.66 |
| Tax Rate(%) | 24.08 | 25.65 | 21.42 | 24.52 | 21.06 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 19.25 | 20.03 | 16.64 | 16.71 | 24.40 |
| EBIT Margin(%) | 18.77 | 18.99 | 17.00 | 16.53 | 22.28 |
| Pre Tax Margin(%) | 18.35 | 18.50 | 16.56 | 15.98 | 21.71 |
| PAT Margin (%) | 13.93 | 13.75 | 13.01 | 12.06 | 17.14 |
| Cash Profit Margin (%) | 16.97 | 17.00 | 15.55 | 14.95 | 19.74 |
| Performance Ratios | |||||
| ROA(%) | 12.93 | 12.93 | 13.78 | 12.94 | 22.40 |
| ROE(%) | 16.89 | 16.53 | 18.59 | 18.72 | 31.33 |
| ROCE(%) | 22.50 | 22.40 | 22.89 | 23.82 | 39.76 |
| Asset Turnover(x) | 0.93 | 0.94 | 1.06 | 1.07 | 1.31 |
| Sales/Fixed Asset(x) | 2.16 | 2.33 | 2.62 | 2.42 | 2.49 |
| Working Capital/Sales(x) | 1.59 | 1.55 | 1.53 | 1.83 | 2.30 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 0.46 | 0.43 | 0.38 | 0.41 | 0.40 |
| Receivable days | 65.99 | 69.35 | 72.63 | 78.56 | 67.57 |
| Inventory Days | 97.24 | 87.89 | 81.36 | 97.65 | 84.73 |
| Payable days | 91.59 | 87.70 | 85.31 | 93.88 | 85.57 |
| Valuation Parameters | |||||
| PER(x) | 26.48 | 21.89 | 11.99 | 10.10 | 8.67 |
| PCE(x) | 21.62 | 17.65 | 10.07 | 8.05 | 7.44 |
| Price/Book(x) | 4.08 | 3.33 | 1.83 | 1.68 | 2.31 |
| Yield(%) | 0.36 | 0.40 | 0.71 | 0.55 | 0.50 |
| EV/Net Sales(x) | 3.58 | 2.86 | 1.36 | 1.04 | 1.35 |
| EV/Core EBITDA(x) | 15.68 | 12.23 | 6.32 | 5.18 | 5.35 |
| EV/EBIT(x) | 18.22 | 14.32 | 7.27 | 6.08 | 5.97 |
| EV/CE(x) | 3.77 | 2.97 | 1.41 | 0.94 | 1.51 |
| M Cap / Sales | 3.84 | 3.15 | 1.72 | 1.25 | 1.49 |
| Growth Ratio | |||||
| Net Sales Growth(%) | 20.46 | 17.56 | 24.23 | 8.33 | 21.33 |
| Core EBITDA Growth(%) | 17.68 | 27.69 | 32.55 | -13.16 | 79.82 |
| EBIT Growth(%) | 18.61 | 25.36 | 35.48 | -17.47 | 86.93 |
| PAT Growth(%) | 21.51 | 18.68 | 42.02 | -21.68 | 97.54 |
| EPS Growth(%) | 21.32 | 17.80 | 30.32 | -21.77 | 101.63 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | 0.01 | 0.01 | 0.02 | 0.04 | 0.02 |
| Current Ratio(x) | 4.62 | 4.78 | 4.91 | 3.22 | 3.02 |
| Quick Ratio(x) | 2.85 | 3.19 | 3.49 | 2.11 | 1.67 |
| Interest Cover(x) | 44.22 | 38.80 | 37.99 | 30.31 | 38.84 |
| Total Debt/Mcap(x) | - | - | 0.01 | 0.02 | 0.01 |
Compare Financial Ratios of peers of MARKSANS PHARMA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| MARKSANS PHARMA | ₹8,246.0 Cr | 2.3% | 10.2% | -33% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹405,452.0 Cr | -0.3% | 6% | -10.5% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,089.0 Cr | 3.9% | 18.6% | 14.5% | Stock Analytics | |
| CIPLA | ₹121,299.0 Cr | -5.2% | NA | 2.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹120,456.0 Cr | -1% | -1.2% | 8.7% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,965.9 Cr | -6.8% | -2.1% | -8.4% | Stock Analytics | |
MARKSANS PHARMA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MARKSANS PHARMA | 2.3% |
10.2% |
-33% |
| SENSEX | -0.3% |
4.5% |
5.7% |
You may also like the below Video Courses